Barinthus Biotherapeutics Plc's Competitiveness
A competitive positioning analysis and financial ratio benchmarking of Barinthus Biotherapeutics Plc (BRNS) against its publicly traded competitors: sales growth, net income, profitability, valuation and market share, plus each peer's market capitalization, revenue, income and employees. Free below: the top 5 peers. Subscriber access adds the full competitor list and CSV downloads.
Key Findings: Barinthus Biotherapeutics Plc vs Its Competitors
- Peer revenue share: Barinthus Biotherapeutics Plc accounted for 100.0% of combined revenue among its tracked peer group.
Every figure above is sourced and cited in detail further down this page (Market Structure, Profitability & Cost Structure, Productivity vs Peers).
BRNS Sales vs. its Competitors, Q2 2026
Barinthus Biotherapeutics Plc generated 100.00 % of the combined sales of its peer group.
Barinthus Biotherapeutics Plc's Competitor Quality Breadth
Share of each group, trailing 12 months: profitable (net margin > 0), expanding (revenue growth > 0), growing faster than the industry's own median, and financially distressed (Piotroski F-Score of 2 or below).
| Entity | Profitable | Expanding | Above Industry Growth | Distressed |
|---|---|---|---|---|
| Barinthus Biotherapeutics Plc | - | - | - | - |
| Competitors combined (1) | - | - | - |
Source: CSIMarket API, trailing 12 months. Altman Z-Score is not shown here: it is not populated in the underlying data for any company. Percentages are of companies in each group that report the relevant metric, not of the full group size.
BRNS Stock Performance relative to its Competitors
5 Best-Performing Tracked Competitors, Trailing 12 Months
| # | Competitor | TTM Share Price Return | vs U.S.A. 500 |
|---|---|---|---|
| 1 | Inovio Pharmaceuticals Inc | 282.9% | Outperformed |
TTM share price return and U.S.A. 500 outperformance for Barinthus Biotherapeutics Plc's best-performing tracked competitors requires a Commercial License.
Source: CSIMarket API, trailing 12 months.
Barinthus Biotherapeutics Plc's Comment on Competition and Industry Peers
Publicly Traded Peers of Barinthus Biotherapeutics Plc
Revenue and income for trailing 12 months, in millions of $, except employees| Company | Market Cap | Revenues |
|---|---|---|
| Barinthus Biotherapeutics Plc | 30.23 | - |
| Inovio Pharmaceuticals Inc | 95.49 | 8.14 |
| SUBTOTAL | 125.72 | 8.14 |
Sources: Barinthus Biotherapeutics Plc's official press releases and regulatory filings; CSIMarket.com's market research; and the financial filings and press releases of the other companies cited.
Updated on:
Focus of this report: publicly traded companies. Ten additional tables on Barinthus Biotherapeutics Plc versus competitors, including market share analysis, are in the navigation menu under Competition. To download the tables, please subscribe.
Barinthus Biotherapeutics Plc's Competitors Named by the Company
Competitive relationships identified from SEC filings and corroborating sources, each with a basis and confidence.| Competitor | Basis | Confidence |
|---|---|---|
| Shingrix | Named by the company | 85% |
| CanSino | Named by the company | 85% |
| Inovio Pharmaceuticals Inc | Named by the company | 85% |
| Medicines Co | Named by the company | 85% |
Filing basis, confidence, active dates and source counts for Barinthus Biotherapeutics Plc's named competitors require a Commercial License.
Methodology: relationships are extracted from SEC filings (named-competitor disclosures) and corroborating sources. Named by the company = explicitly disclosed as a competitor; Inferred = derived from corroborating signals. Confidence reflects evidence strength.
Barinthus Biotherapeutics Plc's Business Segment Mix vs Peers
Revenue by operating segment or division, as named and reported by each company. Segment names are the filer's own and are not standardized across companies. Do not assume a same-named or similarly-named segment is defined identically between two companies. Shares are of each company's own total revenue and are not required to sum to 100% (intersegment revenue, unallocated items).| Company | Largest Segment |
|---|---|
| Inovio Pharmaceuticals Inc | Reportable 100.00 % |
Source: operating segment revenue as reported in each company's SEC filings (10-K/10-Q), via the CSIMarket API, leaf-level reportable segments only (parent roll-up segments are excluded where sub-segments are separately disclosed).
Barinthus Biotherapeutics Plc's Productivity vs Peers Comparison
Revenue and income per employee, trailing 12 months, in $; market cap in millions of $| Company | Market Cap | Revenue / Employee | Income / Employee |
|---|---|---|---|
| Barinthus Biotherapeutics Plc | 30 | - | -2,986,214 |
| Inovio Pharmaceuticals Inc | 95 | 72,710 | -602,027 |
| PEERS TOTAL | 95 | 72,710 | -602,027 |
Barinthus Biotherapeutics Plc's Position in Industry Market Structure
Market-capitalization share and concentration across all 498 companies in Barinthus Biotherapeutics Plc's industry classification, broader than the peer set above. Market cap in millions of $.Barinthus Biotherapeutics Plc ranks #0 of 498 companies by market capitalization in its industry, holding 0.00 % of total industry market cap. The industry's Herfindahl-Hirschman Index (HHI) is 827, indicating a unconcentrated market structure (U.S. antitrust guidance: below 1,500 unconcentrated, 1,500 to 2,500 moderately concentrated, above 2,500 highly concentrated).
| Rank | Company | Market Cap | Industry Share |
|---|---|---|---|
| 1 | Eli Lilly And Company | 1,062,533 | 19.39 % |
| 2 | Johnson and Johnson | 664,610 | 12.13 % |
| 3 | Beone Medicines Ltd | 545,679 | 9.96 % |
| 4 | Abbvie Inc | 467,633 | 8.54 % |
| 5 | Merck and Co Inc | 1,234 | 5.2% |
| 6 | Novartis Ag | 1,234 | 5.2% |
| 7 | Abbott Laboratories | 1,234 | 5.2% |
| 8 | Novo Nordisk A | 1,234 | 5.2% |
| 9 | Pfizer Inc | 1,234 | 5.2% |
| 10 | Vertex Pharmaceuticals Inc | 1,234 | 5.2% |
| 0 | Barinthus Biotherapeutics Plc | 30 | 0.00 % |
Market cap and industry share for the rest of Barinthus Biotherapeutics Plc's industry peers requires a Commercial License.
Source: CSIMarket API (daily market-structure computation) across CSIMarket's industry classification, market capitalization as of 2026-09-18.
Barinthus Biotherapeutics Plc's Valuation vs Competitive Position
Valuation multiples vs the Major Pharmaceutical Preparations industry average (341 companies, excluding loss-making/negative-equity outliers), alongside returns on capital for context on whether a premium or discount lines up with measurably stronger or weaker returns.| Metric | Company | Industry Average | Difference |
|---|---|---|---|
| P/E | - | 25.1x | - |
| EV / EBITDA | - | 17.3x | - |
| P/B | 0.4x | 4.5x | -4.1x |
| Return on Equity | -59.20 % | industry aggregate | -76.45 % |
| Return on Invested Capital | -26.59 % | -2.95 % (avg) | -23.64 % |
Source: CSIMarket API, trailing 12 months. A valuation premium or discount is not, by itself, a judgment of over- or under-valuation. Compare it against the return and growth context shown elsewhere on this page.
Barinthus Biotherapeutics Plc's Multi-Year Financial Trajectory
Fiscal-year revenue growth, operating margin, return on invested capital and P/E, as reported in SEC filings.| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue Growth | - | 500.00 % | - | - | - |
| Operating Margin | -16,873.51 % | -9.04 % | - | - | - |
| Return on Invested Capital | -12.44 % | -0.78 % | - | -20.31 % | -33.22 % |
| P/E | - | - | - | - | - |
Source: CSIMarket API, fiscal-year figures. P/E is this company's own historical ratio at each fiscal year end and can swing sharply around an earnings trough: that is real, not a data error.
Barinthus Biotherapeutics Plc's Competitive Forces (Porter's Five Forces)
Only the forces this data can support honestly are shown; the other three are marked as such rather than guessed.| Force | Assessment | Basis |
|---|---|---|
| Competitive Rivalry | High | Industry HHI of 827 (see Industry Market Structure & Concentration above) |
| Supplier Power | Not covered on this page | See Barinthus Biotherapeutics Plc's dedicated suppliers page for concentration and dependency data |
| Buyer Power | Not covered on this page | See Barinthus Biotherapeutics Plc's dedicated customers page for concentration and dependency data |
| Threat of Substitutes | - | No systematic data source for cross-product substitution exists in this system; not estimated |
Note: this is a partial, data-grounded application of the framework, not a complete strategic assessment. Rivalry and barriers-to-entry readings are mechanical translations of the HHI and capital-intensity figures shown elsewhere on this page, not independent judgments.
Barinthus Biotherapeutics Plc's SWOT
Every point below is a fixed rule applied to a metric already shown elsewhere on this page (Market Structure, Profitability, Valuation, Run-Rate, Stock Performance, Quality Breadth) not an independent strategic assessment. A blank quadrant means no rule was met, not that none apply.Strengths
No rule matched.
Weaknesses
- Return on equity 76.5 points below the industry aggregate.
- Underperforming the U.S.A. 500 over the trailing 12 months.
Opportunities
- A meaningful share of tracked competitors (100.00 %) show financial-distress signals, a possible opening to gain share.
Threats
No rule matched.
Methodology: mechanical, rule-based SWOT. Each bullet reuses a figure already sourced and cited elsewhere on this page; nothing here is generated narrative or independent analyst judgment.
Barinthus Biotherapeutics Plc's Financial Strength vs Peers Comparison
Quick ratio, working capital, debt to equity and asset turnover, trailing 12 months| Company | Quick Ratio | Working Capital | Debt / Equity |
|---|---|---|---|
| Barinthus Biotherapeutics Plc | 6.10 | 6.79 | - |
| Inovio Pharmaceuticals Inc | 0.75 | 1.02 | - |
Quick ratio = cash / current liabilities; working capital ratio = current assets / current liabilities; asset turnover = revenue / total assets. Peers in the Blank Checks industry are excluded.
Barinthus Biotherapeutics Plc's Revenue and Income Growth vs Peers
Quarterly revenue and net income growth, year over year and quarter over quarter| Company | Period | Revenue Y/Y | Income Y/Y |
|---|---|---|---|
| Barinthus Biotherapeutics Plc | Q2 2026 | - | - |
| Inovio Pharmaceuticals Inc | Q2 2026 | - | - |
| PEERS TOTAL | - | - |
Growth is shown only where both periods are positive. Peers in the Blank Checks industry are excluded.
Barinthus Biotherapeutics Plc's Peers' Costs of Sales and Capital Expenditures
Context for revenue growth: peer costs and capex, year over year and quarter over quarter| Company | Period | Costs Y/Y | Capex Y/Y |
|---|---|---|---|
| Barinthus Biotherapeutics Plc | Q2 2026 | - | - |
| Inovio Pharmaceuticals Inc | Q2 2026 | - | - |
Barinthus Biotherapeutics Plc's Returns and Turnover vs Peers
ROA, ROI and ROE (trailing 12 months), receivables and inventory turnover| Company | ROA | ROI | ROE |
|---|---|---|---|
| Barinthus Biotherapeutics Plc | - | - | - |
| Inovio Pharmaceuticals Inc | - | - | - |
ROA = net income / total assets; ROI = net income / investments; ROE = net income / equity; turnover ratios use trailing 12 month revenue (receivables) and cost of sales (inventory).
Barinthus Biotherapeutics Plc's Valuation vs Peers
P/E, price to sales, PEG, price to cash flow and price to book| Company | P/E | Price / Sales |
|---|---|---|
| Barinthus Biotherapeutics Plc | - | - |
| Inovio Pharmaceuticals Inc | - | 11.73 |
| PEERS AVERAGE | - | 15.44 |
P/E = price / diluted EPS (trailing 12 months); PEG = P/E divided by EPS growth; the average row divides the peers' combined market cap by their combined income, sales, cash flow and equity.